eli lilly sues compounders for selling unapproved copies of tirzepatide Lilly's Popular Weight Loss Drug, Zepbound, Is Getting a Price Cut Lilly sues two compounders over
Description
Tirzepatide (10mg) is a dual GIP and GLP-1 receptor agonist studied for its impact on type 2 diabetes and obesity
Whats new in the NEJM paper (vs the topline release)
The GIP/GLP-1 dual agonist tirzepatide reduced symptoms of obstructive sleep apnea and improved multiple cardiometabolic markers for adults with obesity and obstructive sleep apnea, according to data from the SURMOUNT-OSA trial
The team was patient, answered all my questions, and helped me manage side effects
Clinical eligibility depends on metabolic markers, glucose control, and cardiovascular risknot body weight alone
Last month, a patient came in for her regular cleaning
